Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Timing of aromatase inhibitors added to breast cancer therapy affects cost-effectiveness
March 23rd, 2006
The timing of aromatase inhibitors added to breast cancer therapy affects the cost effectiveness of the therapy. According to a report from Norway, "Several studies have shown aromatase inhibitors administered as monotherapy or sequentially to tamoxifen to improve relapse-free survival in postmenopausal women with early breast cancer. Any difference in cost/utility between the strategies may be of importance to therapy selection." P.E. Lonning of the University of Bergen wrote, "Cost/utility was compared between the different regimens based on the theoretical assumption that costs, benefits and side-effects were similar for each drug and independent...
Source: Women's Health Weekly (2006-03-23)
|
